NMPA (China) approves tegoprazan to treat erosive esophagitis.-Shandong Luoxin Pharmaceutical Group.
-HK inno.N announced that it has obtained product approval from China's National Medical Products Administration (NMPA) for K-CAB (ingredient: tegoprazan), a gastroesophageal reflux disease (GERD).The indication approved in China is for erosive esophagitis.
The approval comes after HK inno.N signed a $95 million technology export contract with Shandong Luoxin Pharmaceutical Group, a Chinese partner, for K-CAB in 2015. Luoxin has submitted an application for approval to NMPA at the end of 2020. Luoxin, which has the exclusive right for K-CAB in China, from production to distribution, plans to release the drug in the second quarter under a local name, "Taixinzan" which means helping great pleasures.
In close partnership with HK inno.N, Luoxin is steadily expanding the indications of K-CAB to include duodenal ulcer and Helicobacter pylori eradication. The company is also trying to expand the dosage form to an injection type from the existing tablet type.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.